Academic Unit of Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK
Neonatal Unit, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
BMJ Paediatr Open. 2022 May;6(1). doi: 10.1136/bmjpo-2022-001460.
Mechanical ventilation is an uncomfortable and potentially painful intervention. Opioids, such as morphine and fentanyl, are used for analgesia and sedation but there is uncertainty whether they reduce pain in mechanically ventilated infants. Moreover, there may be short-term and long-term adverse consequences such as respiratory depression leading to prolonged mechanical ventilation and detrimental long-term neurodevelopmental effects. Despite this, opioids are widely used, possibly due to a lack of alternatives.Dexmedetomidine, a highly selective alpha-2-adrenergic agonist with analgesic and sedative effects, currently approved for adults, has come into use in newborn infants. It provides analgesia and simulates natural sleep with maintenance of spontaneous breathing and upper airway tone. Although data on pharmacokinetics-pharmacodynamics in preterm infants are scant, observational studies report that using dexmedetomidine in conjunction with opioids/benzodiazepines or on its own can reduce the cumulative exposure to opioids/benzodiazepines. As it does not cause respiratory depression, dexmedetomidine could enable quicker weaning and extubation. Dexmedetomidine has also been suggested as an adjunct to therapeutic hypothermia in hypoxic ischaemic encephalopathy and others have used it during painful procedures and surgery. Dexmedetomidine infusion can cause bradycardia and hypotension although most report clinically insignificant effects.The increasing number of publications of observational studies and clinical use demonstrates that dexmedetomidine is being used in newborn infants but data on safety and efficacy are scant and not of high quality. Importantly, there are no data on long-term neurodevelopmental impact on preterm or term-born infants. The acceptance of dexmedetomidine in routine clinical practice must be preceded by clinical evidence. We need adequately powered and well-designed randomised controlled trials investigating whether dexmedetomidine alone or with opioids/benzodiazepines in infants on mechanical ventilation reduces the need for opioids/benzodiazepine and improves neurodevelopment at 24 months and later as compared with the use of opioids/benzodiazepines alone.
机械通气是一种不舒服且可能带来疼痛的干预措施。阿片类药物,如吗啡和芬太尼,被用于镇痛和镇静,但它们是否能减轻机械通气婴儿的疼痛仍存在不确定性。此外,它们可能会带来短期和长期的不良后果,如呼吸抑制导致机械通气时间延长,以及对长期神经发育产生有害影响。尽管如此,阿片类药物仍被广泛使用,这可能是因为缺乏替代品。右美托咪定是一种具有镇痛和镇静作用的高度选择性α-2 肾上腺素能激动剂,目前已获准用于成人,现已在新生儿中使用。它可提供镇痛作用,并模拟自然睡眠,同时保持自主呼吸和上呼吸道通畅。尽管关于早产儿药代动力学-药效学的数据很少,但观察性研究报告称,在使用阿片类药物/苯二氮䓬类药物的同时或单独使用右美托咪定可以减少阿片类药物/苯二氮䓬类药物的累积暴露量。由于右美托咪定不会引起呼吸抑制,因此可以更快地进行撤机和拔管。右美托咪定也被建议用于缺氧缺血性脑病的治疗性低温治疗,还有人在疼痛处理和手术期间使用它。尽管大多数报告显示其临床影响不显著,但右美托咪定输注可能会导致心动过缓和低血压。越来越多的观察性研究和临床应用的出版物表明,右美托咪定正在被用于新生儿,但关于安全性和疗效的数据很少,且质量不高。重要的是,没有关于对早产儿或足月出生婴儿的长期神经发育影响的数据。在常规临床实践中接受右美托咪定之前,必须有临床证据。我们需要进行足够有力和精心设计的随机对照试验,以研究在机械通气的婴儿中,单独使用右美托咪定或与阿片类药物/苯二氮䓬类药物联合使用是否可以减少对阿片类药物/苯二氮䓬类药物的需求,并改善 24 个月及以后的神经发育,与单独使用阿片类药物/苯二氮䓬类药物相比。